<DOC>
	<DOCNO>NCT02413515</DOCNO>
	<brief_summary>To evaluate antihypertensive efficacy tolerability Nifedipine GITS 60mg treat 8 week Chinese hypertensive subject fail achieve BP control starting-dose antihypertensive monotherapy .</brief_summary>
	<brief_title>Blood Pressure Control Nifedipine GITS 60mg Treatment Chinese Hypertensive Subjects Uncontrolled Starting-dose Mono-therapyo-therapy .</brief_title>
	<detailed_description>Study design : 's A prospective , open-label , multicenter , single-arm study . After one- two-week screening period , subject receive Nifedipine GITS 60mg 8 week . The primary objective evaluate antihypertensive efficacy 8-week Nifedipine GITS 60mg treatment Chinese hypertensive subject fail achieve BP control starting-dose antihypertensive mono-therapy . The secondary objective evaluate tolerability Nifedipine GITS 60mg .</detailed_description>
	<mesh_term>Nifedipine</mesh_term>
	<criteria>Subjects eligible include study meet follow criterion : Aged 18 year old , less 65 year ; Either male female BP uncontrolled least 4 week prior antihypertensive monotherapy ( dosage monotherapy start dose angiotensin receptor blocker ( ARB ) , angiotensin convert enzyme inhibitor ( ACEI ) , bblocker ( BB ) , calcium channel blocker ( CCB ) , diuretic ) begin end screening period ( uncontrolled BP define MSSBP ≥140 &lt; 160mmHg and/or MSDBP ≥ 90 &lt; 100mmHg , presence diabetes mellitus : MSSBP ≥130 &lt; 160mmHg and/or MSDBP ≥80 &lt; 100mmHg ) ; Subjects meeting follow criterion exclude study : Known hypersensitivity nifedipine follow excipients , hypromellose , polyethylene oxide , magnesium stearate , sodium chloride , iron oxide red ( E172/C.I.77491 ) , cellulose acetate , polyethylene glycol 3350 , hydroxypropyl cellulose , propylene glycol , titanium dioxide ( E171/C.I.77891 ) Evidence secondary hypertension coarctation aorta , pheochromocytoma , hyperaldosteronism , etc . Severe gastrointestinal tract narrowing ; gastric banding ; kock pouch ( ileostomy proctocolectomy ) Evidence cardiovascular shock Pregnant , possibly pregnant , plan become pregnant lactating woman Received combination ( two two drug combination ) therapy high dosage ( high dosage define high dosage standard recommend starting dosage present label drug ) monotherapy begin end screening period . History cerebrovascular ischemic event ( stroke transient ischemic attack [ TIA ] ) within 6 month History intracerebral hemorrhage subarachnoid hemorrhage History hypertensive retinopathy Any history heart failure , New York Heart Association ( NYHA ) classification III IV Severe coronary heart disease manifest history myocardial infarction unstable angina past 12 month history percutaneous coronary intervention ( PCI ) coronary artery bypass grafting ( CABG ) Clinically significant cardiac valvular disease History arrhythmia Type 1 diabetes mellitus ( DM ) Hyperkalemia history : serum potassium level upper limit normal laboratory range ; Liver disease aspartate transaminase ( AST ) alanine transaminase ( ALT ) level &gt; 3 x upper limit normal ( ULN ) Renal insufficiency , define estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min , hemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>